Human ubiquitin c promoter

FcγRIIb-deficient mice on a C57BL/6 background^{18 (link)} were kindly provided by Jeff Ravetch (Rockefeller University, New York) and Silvia Bolland (National Institutes of Health, NIAID, Bethesda, MD) and crossed to transgenic mice expressing EGFP under the control of the human ubiquitin C promoter³⁸ (Jackson Laboratories) or transgenic mice expressing Venus EYFP under the control of the CD11c promoter³⁹ (obtained from M. Nussenzweig, Rockefeller University, New York, NY). C57BL/6 mice were obtained from Jackson Laboratories or from Charles River Laboratories (Margate, UK). NZB/W F1 were bred in-house from NZB and NZW mice obtained from Harlan UK. CCR7-deficient mice on a C57BL/6 background (strain B6.129P2(C)-Ccr7^tm1Rfor/J, stock number 006621, live repository, aged 8 weeks old) were purchased from Jackson Laboratories. Age matched C57BL/6 JAX mice were used as controls. In all experiments, both male and female mice were used. Mice were maintained in specific-pathogen-free conditions at an Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility at NIAID or at a Home Office-approved facility in the UK. All procedures were approved by the NIAID Animal Care and Use Committee (National Institutes of Health, Bethesda, MD) or were conducted in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986.